Skip to main content
Top
Published in: CEN Case Reports 1/2015

01-05-2015 | Case Report

A case of “hidden” diabetic nephropathy diagnosed by a combination of renal biopsy findings and continuous glucose monitoring system

Authors: Kota Nishihama, Takaya Nakai, Koji Kanai, Tomoko Sugiyama, Hiroki Kosato, Noriko Oka, Masashi Yasutomi, Kazuya Murata, Takahiro Ohnishi, Tadashi Yabana

Published in: CEN Case Reports | Issue 1/2015

Login to get access

Abstract

Although diabetic nephropathy is a microvascular complication of diabetes mellitus, some reports suggest that renal biopsy often shows this pathological change without a diagnosis of diabetes mellitus. Here, we report a case of a 65-year-old man who presented with proteinuria, hypoalbuminemia and hypertension without a diagnosis of diabetes mellitus. He drank alcohol regularly and was a heavy smoker. Renal biopsy revealed a diffuse increase in the mesangial area, mesangial nodules or well-developed hyalinosis, interstitial fibrosis, and arteriosclerosis consistent with the changes of diabetic nephropathy. Although we had initially diagnosed him with idiopathic nodular glomerulosclerosis, use of a continuous glucose monitoring system (CGMS) revealed that the changes in his daily blood glucose concentrations met with the diagnostic criteria of diabetes mellitus. Accordingly, we diagnosed him with diabetic nephropathy and initiated treatment for diabetes mellitus. This case suggests that some cases of diabetic nephropathy may be hidden among patients with impaired glucose tolerance, who are not diagnosed with diabetes mellitus. Use of a CGMS may be helpful in diagnosing this type of “hidden” diabetes mellitus. In addition to diet therapy, smoking control, treatment for hypertension, and strict control of hyperglycemia may be important for these patients.
Literature
1.
go back to reference Chan JY, Cole E, Hanna AK. Diabetic nephropathy and proliferative retinopathy with normal glucose tolerance. Diabetes Care. 1985;8:385–90.CrossRefPubMed Chan JY, Cole E, Hanna AK. Diabetic nephropathy and proliferative retinopathy with normal glucose tolerance. Diabetes Care. 1985;8:385–90.CrossRefPubMed
2.
go back to reference Yoshida A, Morozumi K, Oikawa T, Suganuma T, Aoki J, Sugito K, Koyama K, Fujinami T, Shigematsu H. Nodular glomerulosclerosis in a patient showing impaired glucose tolerance. Nihon Jinzo Gakkai Shi. 1990;32:877–84.PubMed Yoshida A, Morozumi K, Oikawa T, Suganuma T, Aoki J, Sugito K, Koyama K, Fujinami T, Shigematsu H. Nodular glomerulosclerosis in a patient showing impaired glucose tolerance. Nihon Jinzo Gakkai Shi. 1990;32:877–84.PubMed
3.
go back to reference Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ozbay G. Diffuse diabetic glomerulosclerosis in a patient with impaired glucose tolerance: report on a patient who later develops diabetes mellitus. Neth J Med. 2002;60:260–2.PubMed Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ozbay G. Diffuse diabetic glomerulosclerosis in a patient with impaired glucose tolerance: report on a patient who later develops diabetes mellitus. Neth J Med. 2002;60:260–2.PubMed
4.
go back to reference Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol. 2002;33:826–35.CrossRefPubMed Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol. 2002;33:826–35.CrossRefPubMed
5.
go back to reference Kuppachi S, Idris N, Chander PN, Yoo J. Idiopathic nodular glomerulosclerosis in a non-diabetic hypertensive smoker: case report and review of literature. Nephrol Dial Transplant. 2006;21:3571–5.CrossRefPubMed Kuppachi S, Idris N, Chander PN, Yoo J. Idiopathic nodular glomerulosclerosis in a non-diabetic hypertensive smoker: case report and review of literature. Nephrol Dial Transplant. 2006;21:3571–5.CrossRefPubMed
6.
go back to reference Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. INNOVATION study group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–8.CrossRefPubMed Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. INNOVATION study group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–8.CrossRefPubMed
7.
go back to reference Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther. 2011;13:699–703.CrossRefPubMed Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther. 2011;13:699–703.CrossRefPubMed
8.
go back to reference Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60:833–41.CrossRefPubMed Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60:833–41.CrossRefPubMed
10.
go back to reference Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, Senda M, Nako K, Miyata T, Ito S. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension. 2010;56:471–6.CrossRefPubMed Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, Senda M, Nako K, Miyata T, Ito S. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension. 2010;56:471–6.CrossRefPubMed
11.
go back to reference Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32:115–21.CrossRefPubMed Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32:115–21.CrossRefPubMed
12.
go back to reference Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol. 2007;18:2032–6.CrossRefPubMed Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol. 2007;18:2032–6.CrossRefPubMed
13.
go back to reference Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care. 2008;31:2338–43.CrossRefPubMedCentralPubMed Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care. 2008;31:2338–43.CrossRefPubMedCentralPubMed
14.
go back to reference Gu HF, Ma J, Gu KT, Brismar K. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. Front Endocrinol (Lausanne). 2013;3:179. Gu HF, Ma J, Gu KT, Brismar K. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. Front Endocrinol (Lausanne). 2013;3:179.
15.
go back to reference Bergmann S, Siekmeier R, Mix C, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol. 1998;114:269–75.CrossRefPubMed Bergmann S, Siekmeier R, Mix C, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol. 1998;114:269–75.CrossRefPubMed
16.
go back to reference Scott DA, Stapleton JA, Wilson RF, Sutherland G, Palmer RM, Coward PY, Gustavsson G. Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Mol Dis. 2000;26:255–8.CrossRefPubMed Scott DA, Stapleton JA, Wilson RF, Sutherland G, Palmer RM, Coward PY, Gustavsson G. Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Mol Dis. 2000;26:255–8.CrossRefPubMed
17.
go back to reference Obert DM, Hua P, Pilkerton ME, Feng W, Jaimes EA. Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci. 2011;341:126–30.CrossRefPubMedCentralPubMed Obert DM, Hua P, Pilkerton ME, Feng W, Jaimes EA. Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci. 2011;341:126–30.CrossRefPubMedCentralPubMed
18.
go back to reference Ziyadeh FN, Isono M, Chen S. Involvement of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Clin Exp Nephrol. 2002;6:125–9.CrossRefPubMed Ziyadeh FN, Isono M, Chen S. Involvement of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Clin Exp Nephrol. 2002;6:125–9.CrossRefPubMed
Metadata
Title
A case of “hidden” diabetic nephropathy diagnosed by a combination of renal biopsy findings and continuous glucose monitoring system
Authors
Kota Nishihama
Takaya Nakai
Koji Kanai
Tomoko Sugiyama
Hiroki Kosato
Noriko Oka
Masashi Yasutomi
Kazuya Murata
Takahiro Ohnishi
Tadashi Yabana
Publication date
01-05-2015
Publisher
Springer Japan
Published in
CEN Case Reports / Issue 1/2015
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-014-0150-1

Other articles of this Issue 1/2015

CEN Case Reports 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.